Rapport Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Rapport Therapeutics, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-31.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 65% of Healthcare companies in United States.
Cash Cushion Ratio
+38%Cash, after subtracting all debt, equals 38% of its market value (net cash).
Higher than 73% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Rapport Therapeutics, Inc. made a loss over the last year. Rapport Therapeutics, Inc. owes $0.08 for every $1 it owns. Rapport Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossRapport Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.01The share price is 3.01 times Rapport Therapeutics, Inc.'s book value per share, higher than 55% of Healthcare companies in United States.
Market cap
$1.3 BThe total market value of all of Rapport Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 67% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$423 MWhat Rapport Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$8.81Net worth divided by the number of shares. The share price of $26.53 is 3.0 times this, which is the P/B above.
Return on equity (ROE)
-40.0%Rapport Therapeutics, Inc. lost 40.0% of its shareholders' money over the last year, higher than 55% of Healthcare companies in United States.
Owes vs Owns
0.08×Rapport Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Dividend yield
NoneRapport Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossRapport Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashRapport Therapeutics, Inc. held $479 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Rapport Therapeutics, Inc.: $1.3 B ÷ $423 M (30 Jun 2026) = 3.0.
What is Rapport Therapeutics, Inc.'s return on equity?
Rapport Therapeutics, Inc. lost 40.0% of its shareholders' money over the last year, higher than 55% of Healthcare companies in United States.
How much does Rapport Therapeutics, Inc. owe compared with what it owns?
Rapport Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Does Rapport Therapeutics, Inc. pay a dividend?
No. Rapport Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.